Preterm Labor

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

I
IQVIANC - Durham
1 program
1
OBE022Phase 21 trial
Active Trials
NCT03369262Unknown115Est. Aug 2022
H
HologicMA - Marlborough
1 program
Screening To Obviate Preterm BirthN/A1 trial
Active Trials
NCT01868308Completed589Est. Jun 2015
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
fetal lung elastography measurementN/A1 trial
Active Trials
NCT06168149UnknownEst. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IQVIAOBE022
City Therapeuticsfetal lung elastography measurement
HologicScreening To Obviate Preterm Birth

Clinical Trials (3)

Total enrollment: 704 patients across 3 trials

PoC Study of OBE022 in Threatened Preterm Labour

Start: Jan 2018Est. completion: Aug 2022115 patients
Phase 2Unknown
NCT06168149City Therapeuticsfetal lung elastography measurement

The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor

Start: Sep 2023Est. completion: Mar 2024
N/AUnknown
NCT01868308HologicScreening To Obviate Preterm Birth

Screening To Obviate Preterm Birth

Start: Jan 2013Est. completion: Jun 2015589 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space